Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors.
Saved in:
| Title: | Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors. |
|---|---|
| Authors: | Sale MJ; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK. matthew.sale@babraham.ac.uk., Minihane E; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK., Monks NR; Oncology R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD, 20878, USA., Gilley R; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK., Richards FM; Pharmacology and Drug Development Group, Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK., Schifferli KP; Oncology R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD, 20878, USA., Andersen CL; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA., Davies EJ; Oncology R&D, AstraZeneca, Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK., Vicente MA; CRUK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, CB22 3AT, UK., Ozono E; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK., Markovets A; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA., Dry JR; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA., Drew L; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA., Flemington V; Oncology R&D, AstraZeneca, Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK., Proia T; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA., Jodrell DI; Pharmacology and Drug Development Group, Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK., Smith PD; Oncology R&D, AstraZeneca, Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK., Cook SJ; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK. simon.cook@babraham.ac.uk. |
| Source: | Nature communications [Nat Commun] 2019 Nov 14; Vol. 10 (1), pp. 5167. Date of Electronic Publication: 2019 Nov 14. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-019-12409-w |
